Edwards Lifesciences Corporation EW
At closeNov 13, 2026, 4:02 AM EST
Pre-market · Nov 13, 4:02 AM ET
- YTD
- +24.11%
- 1 year
- +23.63%
- Market cap
- 60.84B
- Revenue (ttm)
- 6.67B
- Profit margin
- 15.30%
- EPS (ttm)
- 1.72
- Shares out
- 575.00M
- P/E ratio
- 61.51
- Forward P/E
- 31.26
- YTD return
- +24.11%
- 1-year return
- +23.63%
- Volume
- 4.16M
- Avg volume
- 3.79M
- Open
- 106.07
- Previous close
- 105.81
- Day's range
- 104.93 – 106.77
- 52-week range
- 74.66 – 106.77
- Beta
- 0.83
- Analysts
- Buy
- Price target
- 113.24 (+7.0%)
- Earnings date
- Feb 9, 2027
5D +6.73 (+6.79%)
Key statistics
- Enterprise value
- 57.00B
- PEG ratio
- 2.33
- Price / sales
- 9.12
- Price / book
- 5.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 10.50%
- Free cash flow
- 1.15B
- Total cash
- 4.64B
- Total debt
- 704.50M
- Return on equity
- 9.33%
- Short % of float
- 1.86%
- 50-day average
- 89.78
- 200-day average
- 86.09
Analyst view
Consensus: buy
- Target (low)
- 84.00
- Target (mean)
- 113.24
- Target (high)
- 126.00
- Strong buy5
- Buy20
- Hold4
- Sell0
- Strong sell1
Next earnings
Feb 9, 2027
Expected Feb 9, 2027. Consensus EPS estimate 0.66039.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 9, 2027 | Dec 30, 2026 | 0.66 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.744 | 0.80 | +0.06 | +7.53% |
| Jul 23, 2026 | Jun 30, 2026 | 0.743 | 0.78 | +0.04 | +4.98% |
| Apr 23, 2026 | Mar 31, 2026 | 0.729 | 0.78 | +0.05 | +7.00% |
| Feb 10, 2026 | Dec 31, 2025 | 0.618 | 0.58 | -0.04 | -6.15% |
| Oct 30, 2025 | Sep 30, 2025 | 0.596 | 0.67 | +0.07 | +12.42% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | TD Cowen | main | Buy | Buy |
| Nov 5, 2026 | UBS | main | Buy | Buy |
| Nov 5, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 5, 2026 | Citigroup | main | Buy | Buy |
| Nov 5, 2026 | Leerink Partners | main | Outperform | Outperform |
| Nov 5, 2026 | RBC Capital | main | Outperform | Outperform |
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- edwards.com
News
TD Cowen Maintains Buy on Edwards Lifesciences, Raises Price Target to $121 
Edwards Lifesciences Corporation $EW Stake Trimmed by Candriam S.C.A. 
Edwards Lifesciences Q3 Earnings Call Highlights - UBS Maintains Buy on Edwards Lifesciences, Raises Price Target to $118
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120 
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $117 
Leerink Partners Maintains Outperform on Edwards Lifesciences, Raises Price Target to $112 - RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $115
- Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120
Bernstein Maintains Market Perform on Edwards Lifesciences, Raises Price Target to $106
Your note
Sign in to keep a note on EW — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOBO DONALD E JR | Officer | Sale | Nov 8, 2026 | 152,379 |
| CHOPRA DAVEEN | Officer | Sale | Aug 25, 2026 | 44,324 |
| GALLAHUE KIERAN T. | Director | Stock Award(Grant) | May 7, 2026 | 83,971 |
| LIPPIS DANIEL J | Officer | Sale | Nov 9, 2026 | 40,033 |
| LORANGER STEVEN R | Director | Stock Award(Grant) | May 7, 2026 | 84,369 |
| MISTRAS THEODORA | Chief Financial Officer | Stock Award(Grant) | Jul 8, 2026 | 99,920 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.22% | 58,789,433 | 6.22B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 37,615,952 | 3.98B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.59% | 26,411,402 | 2.80B | Jun 29, 2026 |
| State Street Corporation | 4.58% | 26,321,940 | 2.79B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 3.96% | 22,783,175 | 2.41B | Jun 29, 2026 |
| Wellington Management Group, LLP | 2.93% | 16,827,967 | 1.78B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 18,279,615 | 1.94B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 14,919,502 | 1.58B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.17% | 12,476,018 | 1.32B | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.98% | 11,357,910 | 1.20B | Jul 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.34% | 7,683,257 | 813.35M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 7,490,884 | 792.98M | Sep 29, 2026 |